Ablation of B7-H3 but not B7-H4 results in highly increased tumor burden in a murine model of spontaneous prostate cancer

Cancer Immunology Research

Volumn 3, Issue 8, 2015, Pages 849-854

  Kreymborg, Katharina ^a   Haak, Stefan ^b,c   Murali, Rajmohan ^a   Wei, Joyce ^d   Waitz, Rebecca ^a   Gasteiger, Georg ^a   Savage, Peter A ^e   Van Den Brink, Marcel R M ^a   Allison, James P ^d  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d UNIVERSITY OF TEXAS   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; B7 H3 PROTEIN; CD8 ANTIGEN; GAMMA INTERFERON; MESSENGER RNA; PROTEIN; TESTOSTERONE; UNCLASSIFIED DRUG; V SET DOMAIN CONTAINING T CELL ACTIVATION INHIBITOR 1; B7 ANTIGEN; CD276 PROTEIN, MOUSE; VTCN1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; EX VIVO STUDY; FLOW CYTOMETRY; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOREGULATION; IN VIVO STUDY; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PROSTATE CANCER; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; T LYMPHOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VOLUME; ANIMAL; CELL TRANSFORMATION; DISEASE MODEL; GENE DELETION; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOPHENOTYPING; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; B7 ANTIGENS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; GENE DELETION; HUMANS; IMMUNOPHENOTYPING; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MICE; MICE, KNOCKOUT; PROSTATIC NEOPLASMS; RNA, MESSENGER; TUMOR BURDEN; V-SET DOMAIN-CONTAINING T-CELL ACTIVATION INHIBITOR 1;

EID: 84962022213     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0100     Document Type: Article

References (19)

1. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A 1998;95:7556-61.
2. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410:1107-11.
3. Peggs KS, Quezada SA, Allison JP. Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin Exp Immunol 2009;157:9-19.
4. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survivalwith ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
5. Loos M, Hedderich DM, Friess H, Kleeff J. B7-h3 and its role in antitumor immunity. Clin Dev Immunol 2010;2010:683875.
6. Chapoval AI, Ni J, Lau JS, Wilcox RA, Flies DB, Liu D, et al. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol 2001;2:269-74.
7. Suh WK, Gajewska BU, Okada H, Gronski MA, Bertram EM, Dawicki W, et al. The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol 2003;4:899-906.
8. Greenberg NM, De Mayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 1995;92:3439-43.
9. Wei J, Loke P, Zang X, Allison JP. Tissue-specific expression of B7x protects from CD4 T cell-mediated autoimmunity. J Exp Med 2011;208:1683-94.
10. Waitz R. Enhancement of T cell responses through Ctla-4 blockade combination therapy in a mouse model of prostate cancer. Proquest: Umi Dissertation Publishing; 2011.
11. Zang X, Thompson RH, Al Ahmadie HA, Serio AM, Reuter VE, Eastham JA, et al. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A 2007;104:19458-63.
12. Ittmann M, Huang J, Radaelli E, Martin P, Signoretti S, Sullivan R, et al. Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res 2013;73:2718-36.
13. Tekle C, Nygren MK, Chen YW, Dybsjord I, Nesland JM, Maelandsmo GM, et al. B7-H3 contributes to the metastatic capacity of melanoma cells by modulation of known metastasis-associated genes. Int J Cancer 2012;130:2282-90.
14. Wang L, Kang FB, Shan BE. B7-H3-mediated tumor immunology: friend or foe? Int J Cancer 2014;134:2764-71.
15. Steinberger P, Majdic O, Derdak SV, Pfistershammer K, Kirchberger S, Klauser C, et al. Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains. J Immunol 2004;172:2352-9.
16. Chen C, Shen Y, Qu QX, Chen XQ, Zhang XG, Huang JA. Induced expression of B7-H3 on the lung cancer cells and macrophages suppresses T-cell mediating anti-tumor immune response. Exp Cell Res 2013;319:96-102.
17. Kraan J, Van Den BP, Verhoef C, Grunhagen DJ, Taal W, Gratama JW, et al. Endothelial CD276 (B7-H3) expression is increased in human malignancies and distinguishes between normal and tumour-derived circulating endothelial cells. Br J Cancer 2014;111:149-56.
18. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9.
19. Nishikawa H, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Curr Opin Immunol 2014;27:1-7.